Quotient Bioresearch buys Edinburgh facility and sets up new clinical unit
Mark Egerton, managing director of Quotient Clinical, told Outsourcing-pharma that the new centre, which was previously owned by Charles River Laboratories, broadens the group’s Phase I offering and will serve as a base for its unique 14-C enabled development service.
Egerton explained that, despite the economic downturn, demand for the group’s services has increased approximately 300 per cent in the last 12 months, particularly its “first-in-human” to "proof-of-concept" offering.
He added that growth of the contract research sector over the next few years will be driven by pharma industry for efficiency and innovative science.
